Added
Updated
Insamo
Biotechnology company developing membrane-permeable and orally available cyclic peptide therapeutics.
Founded
2022Biotechnology company developing membrane-permeable and orally available cyclic peptide therapeutics.
Insamo combines machine learning-driven molecular design, ultra high-throughput molecular biology, and parallel synthetic chemistry to generate preclinical candidates. The platform can screen trillions of molecules and identify high-affinity ligands for targets with limited structural or druggability information.
This approach enables the discovery of oral cyclic peptides that retain antibody-like binding while penetrating cell membranes, addressing intracellular targets that are often inaccessible to conventional large-molecule therapeutics.
Insamo's platform leverages proprietary experimental data generated at scale, allowing its ML models to learn from billions of design-synthesize-test iterations. This data advantage supports the optimization of peptide properties such as membrane permeability, oral bioavailability, target affinity, and selectivity.
The integration of automated synthesis and screening with closed-loop machine learning is intended to shorten the time required to advance macrocyclic peptide programs from target nomination toward preclinical development.
Macrocyclic peptide drug discovery remains an emerging modality with limited clinical precedent, so Insamo must generate robust preclinical and clinical evidence that its oral peptides achieve the predicted pharmacokinetics and efficacy.
The field also includes competing platform companies and established modality players investing in peptide, small molecule, and biologic approaches, which could narrow Insamo's differentiation if its data and target selection do not translate into validated programs.